Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan-Cisplatin in Advanced Gastric Cancer
NCT01444521Phase 2Completed
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Apr 2011
- Primary completion
- May 2014
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab, Cisplatin micelle injection (HA132) in gastric cancer (GC), sponsored by Chinese Academy of Medical Sciences. Started Apr 2011; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabCisplatin micelle injection (HA132)
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT01444521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01444521.